Identifying the tests/procedures ordered by neurologists that contribute most to health care expenditures is a critical step in the process of creating the neurology top 5 list for the Choosing Wisely initiative. Using data from the 2007-2010 National Ambulatory Care Medical Survey, we found that $13.3 billion (95% confidence interval 5 $10.1-$16.5 billion) was spent on tests ordered at neurologist visits. The tests/procedures with the highest expenditures were magnetic resonance imaging (MRI; 51% of total expenditures; $7.5 billion), electromyography (EMG; 20% of expenditures; $2.6 billion), and electroencephalography (EEG; 8% of expenditures; $1.1 billion). MRI, EMG, and EEG should receive close scrutiny in the development of the neurology top 5 list. ANN NEUROL 2013; 73:679-683 I n response to unsustainable growth in health care expenditures, 1 the American Board of Internal Medicine launched the Choosing Wisely initiative. 2, 3 As part of this initiative, medical professional societies have been encouraged to identify 5 non-value-added tests or procedures commonly used in their field, whose necessity should be carefully scrutinized. One potential virtue of this approach is that by identifying and decreasing the use of low-value tests/procedures, physicians demonstrate to a skeptical public that they are genuinely protecting patients' interests rather than rationing health care. 3 So far, 9 specialty societies have each developed a top 5 list. Examples of list items include: "Don't obtain imaging studies in patients with non-specific low back pain" and "In the evaluation of simple syncope and a normal neurological examination, don't obtain brain imaging studies (CT or MRI)" (American College of Physicians). 4 The American Academy of Neurology recently joined the Choosing Wisely initiative and plans to release a top 5 list in 2013. 5 A recent critique of the first of the published top 5 lists is that many of the tests/procedures had only marginal, or in some cases negligible, impact on health care costs. 6, 7 As a result, it has been recommended that future top 5 list development efforts should incorporate cost information to ensure that high-impact services are addressed. 6 In this study, we sought to define the tests and procedures associated with the highest expenditures in outpatient neurologic care and identify the clinical scenarios where those tests are most commonly used.
Patients and Methods

Data Set
The National Ambulatory Medical Care Survey (NAMCS) is a nationally representative survey conducted annually by the Centers for Disease Control and Prevention. 8 NAMCS is designed using a 3-stage sampling design (geographic regions, physician practices stratified within specialties, and patient visits within practices) to enable a nationally representative characterization of outpatient office-based care. For this study, we analyzed all neurologist visits in NAMCS from 2007 to 2010. This sample includes data from 125,029 visits, including 6,764 visits by 195 unique neurologists.
Diagnoses
The principal NAMCS diagnosis for each visit (using International Classification of Diseases, 9th Edition, Clinical Modification [ICD-9-CM] codes) was used to categorize diagnoses with Healthcare Cost and Utilization Project multilevel diagnosis Clinical Classifications Software. 9 For these analyses, each principal diagnosis was categorized by the lowest level diagnostic category in which it was classified.
Tests/Procedures
Test/procedure utilization data are abstracted onto the standardized NAMCS survey instrument by provider practices either by checking boxes for specific procedures (magnetic resonance imaging [MRI], computed tomography [CT], x-rays, some laboratory tests, and ultrasound studies) or by handwriting test/procedure names in available additional space if no checkbox is available (eg, electromyography [EMG], electroencephalography [EEG], polysomnography [PSG]). Handwritten tests/ procedures are later translated into ICD-9 procedure codes.
Tests/procedures were included in this study if they appeared in the sample 5 or more times. Laboratory tests were combined into an index variable representing the total number of laboratory tests used in a given patient.
Payments
Payments were determined using the Medicare physician fee schedule and Medicare Clinical Laboratory Fee Schedule for tests/procedures and laboratory tests, respectively. 10, 11 Total payments were calculated by adding all payments for all tests/procedures. The NAMCS survey instrument does not capture what portion of the body was imaged for CT or MRI, and ICD-9-CM procedure codes for EMG and EEG do not offer sufficient detail to determine the average payments associated with these procedures. Consequently, we used all Medicare claims associated with the Health and Retirement Study (HRS) population, 12 a nationally representative sample, to estimate the payments associated with the average test (eg, the average MRI or the average EMG) ordered by a neurologist. To estimate this average for each test, we determined the distribution of test components performed when ordered by a neurologist. In this way, we were able to account for variation in number of body segments tested and protocols. After determining the distribution of test components per average test, we applied the national limit payment amounts for each test component separately and summed these components to determine the payment for an average test. For comparison purposes, the total expenditures on evaluation and management (E&M) services were estimated using a similar approach. The proportion of individual E&M codes used by neurologists was calculated in the Medicare HRS population, and then the cost of the average neurologist visit was estimated by taking a weighted average of national limit payment amounts.
Statistical Analysis
Descriptive statistics using survey weights were used to estimate the number of visits for each diagnosis category, total expenditures for all test categories, and expenditures for all tests by diagnostic categories. All analyses were performed in Stata version 12.1 (StataCorp, College Station, TX).
Results
A total of 58 million (95% confidence interval [CI] 5 44-72 million) visits to the neurologist were identified from 2007 to 2010. The 3 most common diagnostic categories were disorders of the peripheral nervous system, migraine, and back pain ( Table 1) . From 2007 to 2010, a total of $13.3 billion (95% CI 5 $10.1-$16.5 billion) was spent on diagnostic tests ordered at neurologist visits, with a minimum of $3.2 billion spent in every year (Table 2) . MRI accounted for 57% of all diagnostic expenditures ($7.5 billion; 95% CI 5 $5.7-$9.4 billion). EMG accounted for 20% of expenditures ($2.6 billion; 95% CI 5 $1.9-$3.3 billion) and EEG for 8.3% ($1.1 billion; 95% CI 5 $0.7-$1.5 billion). Together, EMG and EEG accounted for 64% of the non-MRI-related expenditures. Expenditures associated with PSG increased over time, but were <5% of total expenditures in 2010. Laboratory testing accounted for only 1.6% of overall expenditures. By comparison, a total of $6.1 billion (95% CI 5 $4.7-$7.6 billion) was spent on all evaluation and management services attributable to neurologists over this time period.
The diagnostic category with the highest single test expenditures was disorders of the peripheral nervous system, with EMG costs of $820 million (95% CI 5 $520 million-$1.1 billion; Fig) . The only other diagnostic category with EMG expenditures >$250 million was "other back problems." The diagnostic category of migraine had the second highest single-test expenditures, with MRI costs of $690 million (95% CI 5 $350 million-$1 billion). In contrast with EMG, MRI had 12 diagnostic categories with expenditures of $250 million or more. For EEG, epilepsy was the only diagnostic category with expenditures totaling >$200 million ( Supplementary Table) . 
Discussion
The Choosing Wisely campaign aims to reduce unsustainable health care expenditures by identifying clinical contexts in which specific tests/procedures may be wasteful. Identifying targets in neurology requires consideration first of the net clinical utility of a given test/procedure and secondarily of financial costs. In this study, we identified the highest-cost tests/procedures in outpatient care ordered by neurologists. Given their contributions to overall expenditures, MRI, EMG, and EEG should receive close scrutiny in the development of the neurology top 5 list, as together these tests account for 84% of all costs attributable to outpatient neurologist care.
Due to their relatively low expenditures, laboratory tests, CT, ultrasound, and other imaging studies should be given a lower priority in the development of the neurology top 5 list. PSG expenditures may increase in importance if the observed increases from 2007 to 2010 continue into the future.
The primary remaining challenge in developing a top 5 list is to identify the specific clinical scenarios where these tests are of sufficiently low value as to be considered unnecessary or even wasteful. 4 Items in top 5 lists are typically written to discourage the use of a specific test within a specific clinical circumstance. 4 We found that the expenditures for MRI were widely dispersed among 12 different diagnostic categories. EMG and EEG expenditures were more concentrated within the diagnostic categories, although those specific categories (eg, disorders of the peripheral nervous system, epilepsy) are sufficiently broad to necessitate additional steps to identify specific clinical scenarios in which these expensive tests do not add value. Given the paucity of data on the net clinical value of tests/procedures, research studies designed to define the value of these tests in specific clinical scenarios are needed to ensure that waste reduction efforts can be based on evidence.
Other strategies are being used to address test/procedure-related expenditures such as recently implemented coding and payment changes for EMG/nerve conduction studies. The impact of such across-the-board cuts on expenditures remains to be determined. Given the magnitude of expenditure difference between MRI, EMG, EEG, and other tests, however, the relative expenditure rankings of these tests is unlikely to change unless there is a substantial decline in expenditures for 1 test. If such broad reimbursement changes do reduce overall expenditures, they may not do so in a way that targets actual waste while preserving value, which is the aim of more focused expenditure-reduction efforts, such as the Choosing Wisely campaign. 13, 14 This study is limited by the available data from the NAMCS data set and the estimates of payments available. These data include little detail on the specifics of tests that were ordered, and thus we standardized costs to the cost of an average test (eg, the average MRI or average EMG FIGURE : Estimated payments for the 5 most costly tests for the 10 most common diagnostic categories. CT 5 computed tomography; EEG 5 electroencephalography; EMG 5 electromyography; MRI 5 magnetic resonance imaging; PSG 5 polysomnography; USD 5 US dollars. [Color figure can be viewed in the online issue, which is available at www.annalsofneurology.org.] ordered by neurologists). This approach should lead to unbiased and conservative (by failing to account for higher payments paid by private insurers) estimates of overall payments, but may introduce some bias for specific clinical scenarios where a more or less expensive version of a test is used compared to the average. Finally, NAMCS offers limited clinical detail on the circumstances surrounding why specific tests were ordered, limiting inferences about the value of the tests/procedures identified here. Without such details, we cannot conclude that any test or procedure is overused; nor can we exclude the possibility of underutilization in appropriate clinical contexts. Rather, these data simply establish which tests/procedures account for the most resources.
